Loading...
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30 mg m(−2), was administered on day 1 by 60′ i.v. infusion, followed by GEM, 1000 mg m(−2)...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2003
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2394291/ https://ncbi.nlm.nih.gov/pubmed/14520442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601284 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|